Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871285 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
A Phase 2 study, sponsored by BioDelivery Sciences International.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01871285 is a Phase 2 study that has completed, run by BioDelivery Sciences International. The registered enrollment target is 39 participants.
The verdict
NCT01871285, a Phase 2 study, has completed, sponsored by BioDelivery Sciences International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine hydrochloride (HCl) buccal film at 50% of their MSE dose without inducing opioid withdrawal or reversing analgesic effects.
Interventions
- DRUG Oxycodone
- DRUG Buprenorphine
- DRUG Placebo capsule
- DRUG Morphine sulfate
- DRUG Placebo film
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871285
The ClinicalTrials.gov registry entry for NCT01871285 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioDelivery Sciences International, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxycodone is the first listed.
NCT01871285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01871285 about?
NCT01871285 is a clinical study titled "Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film". The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine hydrochloride (HCl) buccal film at 50% of their MSE dose without inducing opioid wi...
What is the current status of trial NCT01871285?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2013-06. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01871285?
The interventions under investigation include: Oxycodone (DRUG), Buprenorphine (DRUG), Placebo capsule (DRUG), Morphine sulfate (DRUG), Placebo film (DRUG).
Who is sponsoring clinical trial NCT01871285?
This trial is sponsored by BioDelivery Sciences International, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.